Bovine dialyzable leukocyte extract protects against LPS-induced, murine endotoxic shock

被引:22
作者
Franco-Molina, MA [1 ]
Mendoza-Gamboa, E [1 ]
Castillo-León, L [1 ]
Tamez-Guerra, RS [1 ]
Rodríguez-Padilla, C [1 ]
机构
[1] Univ Autonoma Nuevo Leon, Fac Ciencias Biol, Dept Microbiol & Immunol, Lab Inmunol & Virol, San Nicolas de los Garza, NL, Mexico
关键词
bovine dialyzable leukocyte extract; endotoxic shock; LPS; pro-inflammatory cytokines;
D O I
10.1016/j.intimp.2004.06.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
The pathophysiology of endotoxic shock is characterized by the activation of multiple pro-inflammatory genes and their products which initiate the inflammatory process. Endotoxic shock is a serious condition with high mortality. Bovine dialyzable leukocyte extract (bDLE) is a dialyzate of a heterogeneous mixture of low molecular weight substances released from disintegrated leukocytes of the blood or lymphoid tissue obtained from homogenized bovine spleen. bDLE is clinically effective for a broad spectrum of diseases. To determine whether bDLE improves survival and modulates the expression of pro-inflammatory cytokine genes in LPS-induced, murine endotoxic shock, Balb/C mice were treated with bDLE (1 U) after pretreatment with LPS (17 mg/kg). The bDLE improved survival (90%), suppressed IL-10 and IL-6, and decreased IL-1beta, TNF-alpha, and IL-12p40 mRNA expression; and decreased the production of IL-10 (P<0.01), TNF-alpha (P<0.01), and IL-6 (P<0.01) in LPS-induced, murine endotoxic shock. Our results demonstrate that bDLE leads to improved survival in LPS-induced endotoxic shock in mice, modulating the pro-inflammatory cytokine gene expression, suggesting that bDLE is an effective therapeutic agent for inflammatory illnesses associated with an unbalanced expression of pro-inflammatory cytokine genes such as in endotoxic shock, rheumatic arthritis and other diseases. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:1577 / 1586
页数:10
相关论文
共 28 条
[1]
AMURA CR, 1988, INFECT IMMUN, V3, P5372
[2]
Davenpeck KL, 1998, J IMMUNOL, V161, P6861
[3]
DEBONT SJM, 1996, IMMUNOLOGY INFECT DI, V6, P49
[4]
Differential effects of IL-6 on systemic and central production of TNF: A study with IL-6-deficient mice [J].
DiSanto, E ;
Alonzi, T ;
Poli, V ;
Fattori, E ;
Toniatti, C ;
Sironi, M ;
RicciardiCastagnoli, P ;
Ghezzi, P .
CYTOKINE, 1997, 9 (05) :300-306
[5]
DISANTO E, 1988, NEUROIMMUNOMODULAT, V2, P149
[6]
ESTRADA PS, 1988, INT J IMMUNOPHARMACO, V20, P521
[7]
Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation [J].
HaimovitzFriedman, A ;
CordonCardo, C ;
Bayoumy, S ;
Garzotto, M ;
McLoughlin, M ;
Gallily, R ;
Edwards, CK ;
Schuchman, EH ;
Fuks, Z ;
Kolesnick, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (11) :1831-1841
[8]
Novel agents in the therapy of endotoxic shock [J].
Howe, LM .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (06) :1363-1372
[9]
JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice [J].
Kakutani, M ;
Takeuchi, K ;
Waga, I ;
Iwamura, H ;
Wakitani, K .
INFLAMMATION RESEARCH, 1999, 48 (08) :461-468
[10]
Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: Dependence on timing of immunomodulating intervention [J].
Kalechman, Y ;
Gafter, U ;
Gal, R ;
Rushkin, G ;
Yan, DH ;
Albeck, M ;
Sredni, B .
JOURNAL OF IMMUNOLOGY, 2002, 169 (01) :384-392